FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123832284> ?p ?o ?g. }

• W3123832284 endingPage "1444" @default.
• W3123832284 startingPage "1444.2" @default.
• W3123832284 abstract "Background: The overall occurrence of Herpes zoster (HZ) infections in patients with rheumatoid arthritis (RA) is greater than in the general population although is controversial whether the use of the different disease-modifying antirheumatic drugs (DMARDs) increases this risk. Objectives: To investigate the incidence and factors associate to HZ infections in patients with RA exposed to biologic agents (BA) and small molecule JAK inhibitors (JAKi), and to describe RA disease features at the moment of HZ infection. Methods: Retrospective longitudinal study was conducted. We included RA patients seen at the rheumatology outpatient clinic of tertiary hospital, commencing BA (anti-TNF therapy and no anti-TNF therapy) or JAKi from Jan 2007 until Dec 2017, and followed up until end of study (Dec 2019). The outcome of interest was the occurrence of HZ infection, the diagnosis of HZ events was based on the rheumatologist’s report. Covariables: sociodemographic, clinical, and concomitant treatments including glucocorticoids, conventional synthetic DMARDs (csDMARDs). Survival techniques were used to estimate the incidence of HZ (IR), per 1000 patient-year (PYs) with the respective Confidence Interval [95%CI]. Cox multivariate regression model to compare the risk of HZ was performed. Results were expressed in Hazard ratio (HR). Results: 474 RA patients were included, starting 881 different courses of treatment (1954.86 patients-years of follow-up). 382 (80.6%) were women with a mean (SD) age of 56.9 (15.0) years at first BA. Across all groups of treatments, a total 18 HZ were recorded, events were non-serious and involved 1 or 2 dermatomes. The mean age (SD) at moment of the infection was 62 (11) years and 10 cases were on prednisone > 7.5 mg/day. 13 HZ cases (72.2%) occurred on treatment with anti-TNF treatment (6 with adalimumab, 4 with certolizumab and 1 with infliximab), 4 (22.2%) cases were on treatment with rituximab one occurred during tocilizumab prescription. The overall incidence of HZ was 9.20 cases per 1000PYs [5.80-14.61]. The crude IR was similar between gender, increased with age (Patients < 46 years: 2.17 [0.3-15.4]; >70 years 14.1 [5.8-33.8]), was higher with concomitant use of two csDMARDs (IR: 15.68 [7.8-31.7], and was similar between anti-TNF and non anti-TNF therapy. None HZ event was recorded in patients exposed to JAKi. In the multivariate analysis, age (HR: 1.05, p: 0.006), prednisone dose > 7.5 mg/day (HR: 2.83, p: 0.02) and the concomitant use of two csDMARDs (HR: 2.34 p: 0.039) increase the risk for HZ. Lymphopenia (HR: 2.6; p=0.06) achieved a trend and BA therapy dropped from the model. Conclusion: HZ incidence rate was 9.20 cases per 1000PYs, HZ occurrence in RA patients cannot be attributed solely to the current BA or JAKi treatment and other factors involved must be taking in count as age, concomitant DMARDs prescriptions, and use of glucocorticoids. Our data suggest that preventive strategies for HZ should be developed for patients with RA. Disclosure of Interests: None declared" @default.
• W3123832284 created "2021-02-01" @default.
• W3123832284 creator A5008807870 @default.
• W3123832284 creator A5018239952 @default.
• W3123832284 creator A5024682966 @default.
• W3123832284 creator A5041835945 @default.
• W3123832284 creator A5045467222 @default.
• W3123832284 creator A5063543970 @default.
• W3123832284 creator A5064534346 @default.
• W3123832284 creator A5065547202 @default.
• W3123832284 creator A5075020011 @default.
• W3123832284 creator A5079561425 @default.
• W3123832284 creator A5085479328 @default.
• W3123832284 creator A5086371226 @default.
• W3123832284 date "2020-06-01" @default.
• W3123832284 modified "2023-09-26" @default.
• W3123832284 title "AB0290 HERPES ZOSTER INFECTIONS IN RHEUMATOID ARTHRITIS PATIENTS EXPOSED TO BIOLOGICAL AGENTS AND JAK INHIBITORS. REAL-WORLD EVIDENCE." @default.
• W3123832284 doi "https://doi.org/10.1136/annrheumdis-2020-eular.4465" @default.
• W3123832284 hasPublicationYear "2020" @default.
• W3123832284 type Work @default.
• W3123832284 sameAs 3123832284 @default.
• W3123832284 citedByCount "1" @default.
• W3123832284 countsByYear W31238322842022 @default.
• W3123832284 crossrefType "journal-article" @default.
• W3123832284 hasAuthorship W3123832284A5008807870 @default.
• W3123832284 hasAuthorship W3123832284A5018239952 @default.
• W3123832284 hasAuthorship W3123832284A5024682966 @default.
• W3123832284 hasAuthorship W3123832284A5041835945 @default.
• W3123832284 hasAuthorship W3123832284A5045467222 @default.
• W3123832284 hasAuthorship W3123832284A5063543970 @default.
• W3123832284 hasAuthorship W3123832284A5064534346 @default.
• W3123832284 hasAuthorship W3123832284A5065547202 @default.
• W3123832284 hasAuthorship W3123832284A5075020011 @default.
• W3123832284 hasAuthorship W3123832284A5079561425 @default.
• W3123832284 hasAuthorship W3123832284A5085479328 @default.
• W3123832284 hasAuthorship W3123832284A5086371226 @default.
• W3123832284 hasBestOaLocation W31238322841 @default.
• W3123832284 hasConcept C120665830 @default.
• W3123832284 hasConcept C121332964 @default.
• W3123832284 hasConcept C126322002 @default.
• W3123832284 hasConcept C167135981 @default.
• W3123832284 hasConcept C198451711 @default.
• W3123832284 hasConcept C207103383 @default.
• W3123832284 hasConcept C2777178219 @default.
• W3123832284 hasConcept C2777575956 @default.
• W3123832284 hasConcept C2908647359 @default.
• W3123832284 hasConcept C44249647 @default.
• W3123832284 hasConcept C50382708 @default.
• W3123832284 hasConcept C61511704 @default.
• W3123832284 hasConcept C71924100 @default.
• W3123832284 hasConcept C99454951 @default.
• W3123832284 hasConceptScore W3123832284C120665830 @default.
• W3123832284 hasConceptScore W3123832284C121332964 @default.
• W3123832284 hasConceptScore W3123832284C126322002 @default.
• W3123832284 hasConceptScore W3123832284C167135981 @default.
• W3123832284 hasConceptScore W3123832284C198451711 @default.
• W3123832284 hasConceptScore W3123832284C207103383 @default.
• W3123832284 hasConceptScore W3123832284C2777178219 @default.
• W3123832284 hasConceptScore W3123832284C2777575956 @default.
• W3123832284 hasConceptScore W3123832284C2908647359 @default.
• W3123832284 hasConceptScore W3123832284C44249647 @default.
• W3123832284 hasConceptScore W3123832284C50382708 @default.
• W3123832284 hasConceptScore W3123832284C61511704 @default.
• W3123832284 hasConceptScore W3123832284C71924100 @default.
• W3123832284 hasConceptScore W3123832284C99454951 @default.
• W3123832284 hasIssue "Suppl 1" @default.
• W3123832284 hasLocation W31238322841 @default.
• W3123832284 hasOpenAccess W3123832284 @default.
• W3123832284 hasPrimaryLocation W31238322841 @default.
• W3123832284 hasRelatedWork W1980318567 @default.
• W3123832284 hasRelatedWork W1984273828 @default.
• W3123832284 hasRelatedWork W1987294331 @default.
• W3123832284 hasRelatedWork W2035343580 @default.
• W3123832284 hasRelatedWork W2046399730 @default.
• W3123832284 hasRelatedWork W2094304284 @default.
• W3123832284 hasRelatedWork W2409856569 @default.
• W3123832284 hasRelatedWork W2558297493 @default.
• W3123832284 hasRelatedWork W2736593664 @default.
• W3123832284 hasRelatedWork W4213445964 @default.
• W3123832284 hasVolume "79" @default.
• W3123832284 isParatext "false" @default.
• W3123832284 isRetracted "false" @default.
• W3123832284 magId "3123832284" @default.
• W3123832284 workType "article" @default.